{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:55:35Z","timestamp":1781668535277,"version":"3.54.5"},"reference-count":32,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objective: Heart failure (HF) is a major cause of morbidity in adults with congenital heart disease (ACHD), who may also have limited access to transplant. Intermittent levosimendan administration has shown benefit in advanced HF due to acquired heart disease, but currently, there are no data on ACHD. We aimed to evaluate the effects of this treatment in ACHD patients with advanced heart failure, focusing on both clinical status and objective outcome measures. Materials and Methods: We conducted a single-center retrospective analysis of ACHD patients aged &gt;18 years with advanced HF who received \u2265 three intermittent levosimendan infusions (either 12.5 mg once monthly or 6.25 mg every two weeks over a 6 h infusion) between March 2020 and January 2025 at a tertiary ACHD center. Clinical outcomes during follow-up were compared with those in the year preceding treatment. Primary endpoints included safety and HF-related adverse events, particularly HF hospitalizations. Secondary endpoints included changes in New York Heart Association (NYHA) class, nt-pro-B-natriuretic peptide (nt-proBNP) values, and ventricular systolic function assessed by echocardiography. Results: Twelve patients (median age 44.6 years, 25% female) were included, with heterogeneous congenital diagnoses and advanced HF. Five patients had a systemic right ventricle (sRV) and one had a single ventricle with previous Fontan palliation. During a median follow-up of 1.3 years, intermittent levosimendan was well-tolerated, with no treatment-limiting adverse events. Two patients (16%) required hospitalization for HF during follow-up compared with 8 (66%) in the year preceding treatment. The incidence of HF hospitalizations decreased from 0.83 to 0.20 events per person-year during follow-up (p = 0.03), although findings should be interpreted cautiously given the small sample size and retrospective design. NYHA functional class improved significantly (p = 0.005). While no significant changes were observed in NT-proBNP or left ventricular ejection fraction, patients with a systemic right ventricle (sRV) showed an increase in right ventricular fractional area change (27 \u00b1 7.4% to 30.6 \u00b1 7%, p = 0.02); however, this observation should be regarded as exploratory given the limited sample size. Two deaths occurred, consistent with the severity of the underlying disease and not directly attributable to levosimendan and the Fontan patient received a successful heart and liver transplant. Conclusions: In a small, real-world cohort of ACHD and advanced HF, intermittent levosimendan administration was safe and associated with improved symptoms, reduced HF hospitalizations, and signals of enhanced systemic right ventricular function. These hypothesis-generating findings may help inform future multicenter studies in ACHD patients with advanced HF, suggesting a potential role for intermittent levosimendan in selected patients, while highlighting the need for prospective, adequately powered studies to confirm its efficacy and better define optimal patient selection.<\/jats:p>","DOI":"10.3390\/medicina62061170","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:58:38Z","timestamp":1781661518000},"page":"1170","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intermittent Levosimendan Administration for Advanced Heart Failure Treatment in Adults with Congenital Heart Disease (Levo-ACHD Study)"],"prefix":"10.3390","volume":"62","author":[{"given":"Flavia","family":"Fusco","sequence":"first","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7257-7220","authenticated-orcid":false,"given":"Ippolita","family":"Altobelli","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7896-3629","authenticated-orcid":false,"given":"Vito","family":"Casale","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4283-7824","authenticated-orcid":false,"given":"Nunzia","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-9435","authenticated-orcid":false,"given":"Giovanni Domenico","family":"Ciriello","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-073X","authenticated-orcid":false,"given":"Rosaria","family":"Barracano","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-9696","authenticated-orcid":false,"given":"Assunta","family":"Merola","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Palma","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7416-9728","authenticated-orcid":false,"given":"Giovanni","family":"Papaccioli","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Correra","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-1953","authenticated-orcid":false,"given":"Diego","family":"Colonna","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Scognamiglio","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9941-8500","authenticated-orcid":false,"given":"Berardo","family":"Sarubbi","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijcard.2020.08.047","article-title":"Heart transplantation at a single tertiary adult congenital heart disease centre: Too little, too late?","volume":"322","author":"Rybicka","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.21037\/jtd-23-513","article-title":"Cardiac transplantation in adult congenital heart disease: A narrative review","volume":"15","author":"Meshulami","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.healun.2017.11.010","article-title":"An Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of hospitalization, functional status, and mortality after mechanical circulatory support in adults with congenital heart disease","volume":"37","author":"Cedars","year":"2018","journal-title":"J. Heart Lung Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Masarone, D., Kittleson, M.M., Pollesello, P., Marini, M., Iacoviello, M., Oliva, F., Caiazzo, A., Petraio, A., and Pacileo, G. (2022). Use of Levosimendan in Patients with Advanced Heart Failure: An Update. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216408"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Masarone, D., Kittleson, M.M., Martucci, M.L., Valente, F., Gravino, R., Verrengia, M., Ammendola, E., Contaldi, C., Di Palma, V., and Caiazzo, A. (2022). Levosimendan as a \u201cBridge to Optimization\u201d in Patients with Advanced Heart Failure with Reduced Ejection-A Single-Center Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144227"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.healun.2024.05.010","article-title":"International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates\u20142024","volume":"43","author":"Peled","year":"2024","journal-title":"J. Heart Lung Transplant."},{"key":"ref_7","first-page":"CD011312","article-title":"Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease","volume":"8","author":"Hummel","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wannaz, L., Boillat, L., Perez, M.H., and Di Bernardo, S. (2023). Prophylactic use of levosimendan in preoperative setting for surgical repair of congenital heart disease in children. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1205971"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa080","article-title":"Pulsed Levosimendan in advanced heart failure due to congenital heart disease: A case series","volume":"4","author":"Cranley","year":"2020","journal-title":"Eur. Heart J.-Case Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchf.2019.08.012","article-title":"Advanced Heart Failure in Adults with Congenital Heart Disease","volume":"8","author":"Menachem","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e027819","DOI":"10.1161\/JAHA.122.027819","article-title":"Health-Related Quality of Life and Its Association with Outcomes in Adults with Congenital Heart Disease and Heart Failure: Insight from FRESH-ACHD Registry","volume":"12","author":"Ly","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e010123","DOI":"10.1161\/CIRCHEARTFAILURE.122.010123","article-title":"Considerations for Advanced Heart Failure Consultation in Individuals with Fontan Circulation: Recommendations from ACTION","volume":"16","author":"Lubert","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_15","first-page":"100322","article-title":"Protein-losing enteropathy in Fontan circulation: Pathophysiology, outcome and treatment options of a complex condition","volume":"7","author":"Barracano","year":"2022","journal-title":"Int. J. Cardiol. Congenit. Heart Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101443","DOI":"10.1016\/j.jacadv.2024.101443","article-title":"Propensity Score Analysis of Possible Medication Effects on Outcomes in Patients with Systemic Right Ventricles","volume":"4","author":"Misra","year":"2024","journal-title":"JACC Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/heartjnl-2025-326384","article-title":"Cardiac resynchronisation therapy among adults with a systemic right ventricle: A multicentre experience","volume":"112","author":"Fusco","year":"2026","journal-title":"Heart"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e009848","DOI":"10.1161\/CIRCHEARTFAILURE.122.009848","article-title":"Safety and Efficacy of Sacubitril\/Valsartan in Patients with a Failing Systemic Right Ventricle: A Prospective Single-Center Study","volume":"16","author":"Fusco","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1136\/heartjnl-2022-322332","article-title":"Tolerability and beneficial effects of sacubitril\/valsartan on systemic right ventricular failure","volume":"109","author":"Nederend","year":"2023","journal-title":"Heart"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jchf.2024.01.006","article-title":"Dapagliflozin in Patients with a Failing Systemic Right Ventricle: Results from the DAPA-SERVE Trial","volume":"12","author":"Fusco","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e040302","DOI":"10.1161\/JAHA.124.040302","article-title":"Safety and Efficacy of Dapagliflozin in Patients with Systemic Right Ventricular Dysfunction: DAPA-SRV Trial","volume":"14","author":"Albertini","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/jcpt.12067","article-title":"Pharmacology of levosimendan: Inotropic, vasodilatory and cardioprotective effects","volume":"38","author":"Pathak","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00246-017-1718-2","article-title":"Use of Levosimendan in Postoperative Setting After Surgical Repair of Congenital Heart Disease in Children","volume":"39","author":"Amiet","year":"2018","journal-title":"Pediatr. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: The LION-HEART multicentre randomised trial","volume":"20","author":"Manito","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1002\/ehf2.13670","article-title":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: The LAICA study","volume":"8","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ehf2.14278","article-title":"Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry","volume":"10","author":"Dobarro","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jama.2025.19843","article-title":"Levosimendan to Facilitate Weaning from ECMO in Patients with Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial","volume":"335","author":"Combes","year":"2026","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jchf.2021.01.015","article-title":"Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial","volume":"9","author":"Burkhoff","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cardfail.2025.06.009","article-title":"Oral Levosimendan for the Treatment of Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction: Rationale and Design of the LEVEL Trial","volume":"32","author":"Yaku","year":"2026","journal-title":"J. Card. Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/ejhf.3420","article-title":"Heart failure with preserved ejection fraction risk after aortic coarctation surgery: The hidden threat","volume":"26","author":"Trimarchi","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"24097","DOI":"10.1038\/s41598-021-03317-5","article-title":"The effect of levosimendan on right ventricular function in patients with heart dysfunction: A systematic review and meta-analysis","volume":"11","author":"Hu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1053\/j.jvca.2023.11.020","article-title":"Safety of Levosimendan in Pediatric Patients: An Up-to-Date Systematic Review","volume":"38","author":"Pilia","year":"2024","journal-title":"J. Cardiothorac. Vasc. Anesth."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1170\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:12:30Z","timestamp":1781665950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061170"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061170","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}